193 related articles for article (PubMed ID: 18251464)
21. Monoclonal antibody, Mab 12C3, is a sensitive immunohistochemical marker of early malignant change in epithelial ovarian tumors.
Yamada K; Ohkawa K; Joh K
Am J Clin Pathol; 1995 Mar; 103(3):288-94. PubMed ID: 7872250
[TBL] [Abstract][Full Text] [Related]
22. Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas.
Friedman EL; Hayes DF; Kufe DW
Cancer Res; 1986 Oct; 46(10):5189-94. PubMed ID: 3530435
[TBL] [Abstract][Full Text] [Related]
23. The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b.
Bodyak ND; Mosher R; Yurkovetskiy AV; Yin M; Bu C; Conlon PR; Demady DR; DeVit MJ; Gumerov DR; Gurijala VR; Lee W; McGillicuddy D; Park PU; Poling LL; Protopova M; Qin L; Stevenson CA; Ter-Ovanesyan E; Uttard A; Xiao D; Xu J; Xu L; Bergstrom DA; Lowinger TB
Mol Cancer Ther; 2021 May; 20(5):896-905. PubMed ID: 33722858
[TBL] [Abstract][Full Text] [Related]
24. Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer.
Connor JP; Felder M; Hank J; Harter J; Gan J; Gillies SD; Sondel P
J Immunother; 2004; 27(3):211-9. PubMed ID: 15076138
[TBL] [Abstract][Full Text] [Related]
25. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium.
Chang K; Pastan I; Willingham MC
Int J Cancer; 1992 Feb; 50(3):373-81. PubMed ID: 1735605
[TBL] [Abstract][Full Text] [Related]
26. Binding parameters of monoclonal antibodies reacting with ovarian carcinoma ascites cells.
Mattes MJ; Lloyd KO; Lewis JL
Cancer Immunol Immunother; 1989; 28(3):199-207. PubMed ID: 2924330
[TBL] [Abstract][Full Text] [Related]
27. A revival of bispecific antibodies.
Kufer P; Lutterbüse R; Baeuerle PA
Trends Biotechnol; 2004 May; 22(5):238-44. PubMed ID: 15109810
[No Abstract] [Full Text] [Related]
28. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.
Luiten RM; Warnaar SO; Sanborn D; Lamers CH; Bolhuis RL; Litvinov SV; Zurawski VR; Coney LR
J Immunother; 1997 Nov; 20(6):496-504. PubMed ID: 9409456
[TBL] [Abstract][Full Text] [Related]
29. Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line.
Chang K; Pastan I
Int J Cancer; 1994 Apr; 57(1):90-7. PubMed ID: 8150545
[TBL] [Abstract][Full Text] [Related]
30. Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model.
Gustafsson AM; Bäck T; Elgqvist J; Jacobsson L; Hultborn R; Albertsson P; Morgenstern A; Bruchertseifer F; Jensen H; Lindegren S
Nucl Med Biol; 2012 Jan; 39(1):15-22. PubMed ID: 21958859
[TBL] [Abstract][Full Text] [Related]
31. Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers.
Brinkmann U; Webber K; Di Carlo A; Beers R; Chowdhury P; Chang K; Chaudhary V; Gallo M; Pastan I
Int J Cancer; 1997 May; 71(4):638-44. PubMed ID: 9178820
[TBL] [Abstract][Full Text] [Related]
32. Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody.
Stein R; Basu A; Chen S; Shih LB; Goldenberg DM
Int J Cancer; 1993 Dec; 55(6):938-46. PubMed ID: 8253531
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies.
Wang X; Campoli M; Ko E; Luo W; Ferrone S
J Immunol Methods; 2004 Nov; 294(1-2):23-35. PubMed ID: 15604013
[TBL] [Abstract][Full Text] [Related]
34. The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.
Kersual N; Garambois V; Chardès T; Pouget JP; Salhi I; Bascoul-Mollevi C; Bibeau F; Busson M; Vié H; Clémenceau B; Behrens CK; Estupina P; Pèlegrin A; Navarro-Teulon I
MAbs; 2014; 6(5):1314-26. PubMed ID: 25517316
[TBL] [Abstract][Full Text] [Related]
35. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions.
Spendlove L; Li L; Potter V; Christiansen D; Loveland BE; Durrant LG
Eur J Immunol; 2000 Oct; 30(10):2944-53. PubMed ID: 11069077
[TBL] [Abstract][Full Text] [Related]
36. Characterizing and evaluating the expression of the type IIb sodium-dependent phosphate cotransporter (slc34a2) gene and its potential influence on phosphorus utilization efficiency in yellow catfish (Pelteobagrus fulvidraco).
Chen P; Tang Q; Wang C
Fish Physiol Biochem; 2016 Feb; 42(1):51-64. PubMed ID: 26298316
[TBL] [Abstract][Full Text] [Related]
37. Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1.
Ryuko K; Schol DJ; Snijdewint FG; von Mensdorff-Pouilly S; Poort-Keesom RJ; Karuntu-Wanamarta YA; Verstraeten RA; Miyazaki K; Kenemans P; Hilgers J
Tumour Biol; 2000; 21(4):197-210. PubMed ID: 10867613
[TBL] [Abstract][Full Text] [Related]
38. Establishment of a murine monoclonal antibody against human clear cell carcinoma and analysis of the corresponding antigen.
Nakagawa S; Tsuji Y; Masuda N; Nishiura H; Isojima S
Gynecol Oncol; 1987 Nov; 28(3):318-29. PubMed ID: 2445637
[TBL] [Abstract][Full Text] [Related]
39. Immunopathologic analysis of a panel of mouse monoclonal antibodies reacting with human ovarian carcinomas and other human tumors.
Cordon-Cardo C; Mattes MJ; Melamed MR; Lewis JL; Old LJ; Lloyd KO
Int J Gynecol Pathol; 1985; 4(2):121-30. PubMed ID: 3894261
[TBL] [Abstract][Full Text] [Related]
40. The Ig V
Girola N; Matsuo AL; Figueiredo CR; Massaoka MH; Farias CF; Arruda DC; Azevedo RA; Monteiro HP; Resende-Lara PT; Cunha RL; Polonelli L; Travassos LR
Peptides; 2016 Nov; 85():1-15. PubMed ID: 27575453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
